Changes in weight and glucose tolerance during treatment with mirtazapine.
نویسندگان
چکیده
W eight gain is a serious problem with numerous psychotropic drugs (1), and drug-induced weight gain may be associated with health risks typically linked to obesity such as type 2 diabetes. Some second generation antipsychotics are known to lead to weight gain and to impair glucose tolerance (2), but little is known about the influence of weight gain–inducing novel antidepressants such as mirtazapine on glucose tolerance. In a naturalistic study, we assessed weight, glucose tolerance, and plasma levels of insulin and cortisol, which are major players regarding glucose metabolism (3), in 11 inpatients (7 males and 4 females; age [mean SD]: 46.7 20.5 years; weight: 73.3 5.5 kg) with major depression according to the ICD-10 and Diagnostic and Statistical Manual of Mental Disorders Fourth Edition receiving mirtazapine during psychiatric hospital treatment of 2–6 weeks. After the initial baseline examination, mirtazapine treatment was started and the dosage adjusted according to clinical needs. At baseline and at the end of treatment, patients were weighed and underwent an oral glucose tolerance test (OGTT) over 4 h. During treatment with mirtazapine, subjects gained on average 2.17 1.97 kg (t 3.65, df 10, P 0.004). However, basal serum glucose (102 14 vs. 96 6 mg/dl; t 2.23, df 10, P 0.05) and glucose tolerance as measured by 120-min glucose (150 83 vs. 128 83 mg/dl; t 2.25, df 10, P 0.048) and glucose area under the curve during OGTT (df 10, P 0.028) improved in parallel. Also, 120-min insulin levels decreased during treatment (from 51 27 to 37 34 U/ml; t 2.33, df 10, P 0.042). Indexes of insulin sensitivity (4) showed no statistically significant changes during the treatment period (homeostasis model assessment: from 4.91 1.44 to 5.01 1.19; t 0.22, df 10, P 0.827; Matsuda and DeFronzo index: from 4.42 1.71 to 4.89 2.12, t 1.00, df 10, P 0.339). Cortisol levels did not decrease significantly from baseline to the end of therapy but did between baseline and treatment week 2 (from 195.11 58.29 to 162.98 34.54 g/l; t 2.28, df 9, P 0.049). The present study confirms that treatment with mirtazapine is likely to be associated with weight gain. Although weight gain is expected to impair glucose tolerance, mirtazapine had the opposite effect in the present study. Improved glucose tolerance during treatment with mirtazapine may, at least in part, be mediated by a reduction of cortisol secretion, because cortisol plasma levels are reported to be elevated in depressed patients (5), and it was found that they can be lowered by antidepressant treatment with mirtazapine (6). Usually, depression goes along with a decrease in physical activity, appetite, and food intake but a relative excess of carbohydrates and a preference for sweets (7). Recovery from depression might therefore lead to favorable changes in nutritional preferences and physical activity. Additionally, mirtazapine unfolds -adrenergic antagonism effects by blocking 2-receptors (8). It is possible that this -adrenergic antagonism is responsible for the drop in glucose, similar to the effect of the -adrenergic antagonist doxazosin, which has been reported to lead to a decrease in plasma glucose during OGTT without changing the plasma insulin response (9). Depression has been significantly linked with the development of type 2 diabetes (10), making it highly desirable to gain further knowledge on the effect of antidepressants on glucose metabolism.
منابع مشابه
The relationship between pregnancy weight gain and impaired glucose tolerance test
Impaired glucose tolerance has several adverse effects on growing fetus. In this study we evaluated the effect of excessive weight gain during pregnancy on the risk of glucose intolerance in pregnant women. A case-control study was conducted through which the glucose tolerance status after 100 gram oral glucose intake was compared between 60 pregnant women with maximum 10 weeks of gestation and...
متن کاملMirtazapine may show anti-hyperglycemic effect by decreasing GLUT2 through leptin and galanin expressions in the liver of type 1 diabetic rats
Objective(s): The aim of this study was to explore the molecular mechanism of mirtazapine with respect to energy metabolism in Streptozotocin-induced diabetic liver of rats by immunohistochemistry and Western blot. Materials and Methods: Twenty-one male Sprague-Dawley rats were assigned into 3 groups including control, type 1 diabetes me...
متن کاملدیابت و بارداری
Diabetes during pregnancy is either concurrent diabetes, diagnosed before pregnancy, or ‘gestational diabetes mellitus’ (GDM), first diagnosed in pregnancy. GDM is the commonest metabolic disorder of pregnancy, with a prevalence of one to 14 percent, depending on the reporting team. The prevalence of GDM in Tehran is 4.7%. Diabetes concurrent with pregnancy is diagnosed according to the recent...
متن کاملChanges in plasma nitric oxide metabolites concentration during glucose tolerance test in type 2 diabetic rats
Introduction: Repeated hyperglycemia play an important role in the development of atherosclerosis in diabetic patients. Endothelium is the organ of the first-line defense against atherosclerosis and nitric oxide has a major role in this task. The aim of this study was to determine changes in plasma nitric oxide metabolites concentration during glucose tolerance test in type 2 diabetic rats. Me...
متن کاملEffects of Teucrium Polium Aerial Parts extract on oral glucose tolerance tests and pancreas histopathology in Streptozocin-induced diabetic rats
Teucrium polium can reduce serum glucose. There are few reports in the literature related to this subject and the resolution of this mechanism requires further experiments. The aim of the present study was to evaluate the effects of Teucrium polium aerial parts extracts on oral glucose tolerance tests and pancreas histology in streptozocin-induced diabetic rats. In order to prepare the aqueous ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Diabetes care
دوره 29 1 شماره
صفحات -
تاریخ انتشار 2006